GENITOURINARY DRUGS:

TREATMENT FOR BENIGN PROSTATIC HYPERPLASIA (BPH) or LOWER URINARY TRACT SYMPTOMS (LUTS)

	INSTIs		NNRTIS		Pls	
	 BICTEGRAVIR (Biktarvy) DOLUTEGRAVIR (Tivicay, Triumeq, Juluca) RALTEGRAVIR (Isentress) 	COBICISTAT (Stribild,	 DORAVIRINE (Pifeltro, Delstrigo) RILPIVIRINE (Edurant, Complera, Odefsey, Juluca) 	Atripla) ETRAVIRINE (Intelence) NEVIRAPINE (Viramune)	Boosted with ritonavir (Norvir) or cobicistat • ATAZANAVIR (Reyataz, Evotaz) • DARUNAVIR (Prezista, Prezcobix, Symtuza) • LOPINAVIR (Kaletra)	
5 ALPHA REDUCTASE INHIBITORS						
Dutasteride (Avodart)		Potential for ↑ dutasteride		Potential for ↓ dutasteride	Potential for ↑ dutasteride	
• Finasteride (Proscar)						
ALPHA 1 ADRENERGIC RECEPTOR BLOCKERS (NON-SELECTIVE)						
• Doxazosin (Cardura)		Potential for \uparrow doxazosin		Potential for ↓ doxazosin	Potential for † doxazosin	
• Terazosin (Hytrin)		Potential for ↑ terazosin		Potential for ↓ terazosin	Potential for ↑ terazosin	
ALPHA 1 ADRENERGIC RECEPTOR BLOCKERS (SELECTIVE)						
• Alfuzosin (Xatral)		Potential for ↑ alfuzosin and toxicity		Potential for	Potential for \uparrow alfuzosin and toxicity	


	INSTIs		NNRTIS		Pls
	 BICTEGRAVIR (Biktarvy) DOLUTEGRAVIR (Tivicay, Triumeq, Juluca) RALTEGRAVIR (Isentress) 	• ELVITEGRAVIR/ COBICISTAT (Stribild, Genvoya)	 DORAVIRINE (Pifeltro, Delstrigo) RILPIVIRINE (Edurant, Complera, Odefsey, Juluca) 	 EFAVIRENZ (Sustiva, Atripla) ETRAVIRINE (Intelence) NEVIRAPINE (Viramune) 	Boosted with ritonavir (Norvir) or cobicistat • ATAZANAVIR (Reyataz, Evotaz) • DARUNAVIR (Prezista, Prezcobix, Symtuza) • LOPINAVIR (Kaletra)
• Silodosin (Rapaflo)		Potential for ↑ silodosin. Use 4 mg dose and monitor for toxicity.		Potential for ↓ silodosin	Potential for † silodosin. Use 4 mg dose and monitor for toxicity.
• Tamsulosin (Flomax CR)		Potential for ↑ tamsulosin. Use 0.4 mg dose and monitor for toxicity.		Potential for ↓tamsulosin	Potential for † tamsulosin. Use 0.4 mg dose and monitor for toxicity.
PDE5 INHIBITORS					
● Tadalafil <i>(Cialis)</i>		Potential for ↑ tadalafil but dose adjustment not required (*for 5 mg daily dose only)		Potential for ↓ tadalafil	Potential for ↑ tadalafil but dose adjustment not required (*for 5 mg daily dose only)

^{*}NB: for tadalafil, this table refers to the daily dose of 5 mg for benign prostatic hyperplasia. Please refer to "Genitourinary Drugs: PDE5 Inhibitors for Erectile Dysfunction (ED) or Pulmonary Arterial Hypertension (PAH)" table for recommendations on higher or intermittent dosing of tadalafil with antiretrovirals.

Mechanism of Drug Interactions, Management and Monitoring

Class	Mechanism of Interaction	Main Interacting ARVs	Management	Monitoring
5 alpha reductase inhibitors	Inhibition of CYP3A4 (dutasteride)	Ritonavir and cobicistat- boosted protease inhibitors and elvitegravir	Finasteride may be used	Dutasteride toxicity: erectile dysfunction, decreased libido
	Induction of CYP3A4 (dutasteride)	Efavirenz, etravirine, nevirapine	Finasteride may be used	Dutasteride efficacy
Alpha 1 adrenergic blockers (non-selective)	Inhibition of CYP3A4 (doxazosin, terazosin)	Ritonavir and cobicistat- boosted protease inhibitors and elvitegravir	Adjust dose according to efficacy/toxicity	Toxicity: hypotension, dizziness, headache, asthenia, nasal congestion
	Induction of CYP3A4 (doxazosin, terazosin)	Efavirenz, etravirine, nevirapine		Doxazosin & terazosin efficacy
Alpha 1 adrenergic blockers (selective)	Inhibition of CYP3A4 (alfuzosin>silodosin, tamsulosin)	Ritonavir and cobicistat- boosted protease inhibitors and elvitegravir	Alfuzosin: consider low-dose silodosin or tamsulosin with monitoring or change antiretroviral regimen.	Toxicity: hypotension, dizziness, headache, diarrhea, nasal congestion
	Induction of CYP3A4 (all)	Efavirenz, etravirine, nevirapine		Alfuzosin, silodosin, tamsulosin efficacy
PDE5 Inhibitor Tadalafil 5 mg daily dose ONLY*	Inhibition of CYP3A4 (tadalafil)	May be used with all ARVs	Daily tadalafil 5 mg may be used without dose adjustment. May ↓ to 2.5 mg daily based on tolerability.	Monitor for toxicity: headache, dyspepsia, flushing, back pain, nasal congestion.

^{*}Please refer to "Genitourinary Drugs: PDE5 Inhibitors for Erectile Dysfunction (ED) or Pulmonary Arterial Hypertension (PAH)" table for recommendations on higher or intermittent dosing of tadalafil with antiretrovirals





Printed with the assistance of an unrestricted educational grant from:









© 2019 Canadian HIV and Viral Hepatitis Pharmacists Network (CHAP) All listed brands are trademarks or registered trademarks of their respective owners.



